Outcome MeasureSafety / Adverse Events

QTc

Corrected QT Interval

2 Papers in Blossom

Clinical Thresholds

300600
Normal
Score 300–450
Borderline prolonged
Score 451–480
Prolonged
Score 481–499
High risk (torsades de pointes)
Score 500–600

Outcome Data Across Studies

Reported results for QTc across 2 studies with quantitative data.

Outcome data across 5 study arm–timepoint observations
SD
Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study
2021Primary
Ibogaine single dose(experimental)014411.044.9—
Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study
2021Primary
Ibogaine single dose(experimental)114513.0——
LSD microdosing in major depressive disorder: results from an open-label trial
2026Safety
LSD microdose(experimental)0—408.820.2—
LSD microdosing in major depressive disorder: results from an open-label trial
2026Safety
LSD microdose(experimental)57—408.524.0—
LSD microdosing in major depressive disorder: results from an open-label trial
2026Safety
LSD microdose(experimental)114—413.627.6—

Papers Using QTc

Open Accessindividual

LSD microdosing in major depressive disorder: results from an open-label trial

This open-label Phase IIa trial (n=19, 15 male) found that an 8-week regimen of microdosed LSD (8μg initially, then 6-20μg twice weekly) for major depressive disorder was well-tolerated with no serious adverse events or cardiac valvulopathy, achieved 59.5% reduction in MADRS scores sustained for six months, and had only one withdrawal due to anxiety.

Published
Journal
Neuropharmacology
Authors
Daldegan-Bueno, D., Donegan, C. J., Sumner, R. L., Forsyth, A., Evans, W. J., Alshakhouri, M., Reynolds, L. M, Roop, P., Ponton, R., Smith, T., Hoeh, N. R., Allen, N., Sundram, F., Menkes, D. B., Muthukumaraswamy, S.
Open Accessindividual

Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study

This open‑label study (n=14) of opioid‑dependent patients given a single 700 mg per 70kg dose of ibogaine‑HCl, treatment produced clinically relevant but reversible cardiac and cerebellar toxicity. The mean maximal QTc(F) prolongation was 95 ms, with 50% of participants exceeding 500 ms, accompanied by bradycardia and severe transient ataxia. Psychomimetic and withdrawal effects were generally manageable, and no torsades de pointes were observed.

Published
Journal
Addiction
Authors
Knuijver, T., Schellekens, A., Belgers, M., Donders, R., Kramers, C., Verkes, R. J.

Quick Facts

Full Name
Corrected QT Interval
Domain
Safety / Adverse Events
Papers Indexed
2
Score Range
300–600
Interpretation
Lower = better
Unit
milliseconds
All Measures